GEFITINIB PHARMACODYNAMICS PATHWAY (PW:0000871)

View Ontology Report

Description

Gefitinib belongs to a class of tyrosine kinase inhibitors (TKI) designed to compete with ATP for binding into the ATP binding pocket of mutated or over-expressed receptor and thus inhibit its tyrosine kinase activity and the signaling events downstream of it. Gefitinib along with erlotinib have been used to target epidermal growth factor receptor, Egfr. Gefitinib, presented here, was among the first and the most widely used TKI for use in the treatment of locally advanced or metastatic non-smal

Pathway Diagram:

Ariadne Genomics Inc. gefitinib other gefitinib metabolites O-desmethyl-gefitinib Egfr ---> gefitinib resistance gefitinib resistance Egfr ---- O-desmethyl-gefitinib ATP ---| Egfr ATP gefitinib pharmacokinetics pathway Egfr ---- gefitinib Egfr ---- other gefitinib metabolites epidermal growth factor/neuregulin signaling pathway ---| non-small cell lung cancer pathway epidermal growth factor/neuregulin signaling pathway ---| Carcinoma, Non-Small-Cell Lung Carcinoma, Non-Small-Cell Lung non-small cell lung cancer pathway Egfr epidermal growth factor/neuregulin signaling pathway Egfr ---| epidermal growth factor/neuregulin signaling pathway
GO TO:

Genes in Pathway:

show annotations for term's descendants       view all columns
gefitinib pharmacodynamics pathway term browser
Symbol Object Name JBrowse Chr Start Stop Reference
G Egfr epidermal growth factor receptor JBrowse link 14 99,919,485 100,104,136 RGD:5135288
RGD:10402751

Additional Elements in Pathway:

(includes Gene Groups, Small Molecules, Other Pathways..etc.)
Object TypePathway ObjectPathway Object Description
Small MoleculeATPadenosine triphosphate
DiseaseCarcinoma, Non-Small-Cell lungentry point to the respiratory disease portal
Pathwayepidermal growth factor/neuregulin signaling pathwayEpidermal growth factor/neuregulin signaling pathway plays a central role in the regulation of cell growth, differentiation, proliferation and survival
Small MoleculegefitinibIressa; ZD1839 (AstraZeneca Inc.)
Pathwaynon-small cell lung cancer pathwayLung cancer, a major cause of cancer mortality, has been assigned to two types: small-cell (SCLC) and non-small cell lung cancer (NSCLC). The first, an extremely aggressive form of cancer accounts for ~20% of cases while the second accounts for the remaining ~80%.
Small MoleculeO-desmethyl-gefitinibmain metabolite
Pathwaygefitinib pharmacokinetics pathwayThe pathway of processing - absorption, distribution, metabolism or elimination - of gefitinib

Pathway Gene Annotations

Disease Annotations Associated with Genes in the gefitinib pharmacodynamics pathway
Disease TermsGene Symbols
Acute Kidney InjuryEgfr
Acute Lung InjuryEgfr
AdenocarcinomaEgfr
Adenocarcinoma of LungEgfr
Adenocarcinoma, Bronchiolo-AlveolarEgfr
Adenomatous Polyposis ColiEgfr
Adrenocortical CarcinomaEgfr
Alzheimer DiseaseEgfr
Aortic Valve InsufficiencyEgfr
Aortic Valve StenosisEgfr
Arthritis, ExperimentalEgfr
AsthmaEgfr
Bile Duct NeoplasmsEgfr
Brain NeoplasmsEgfr
Breast NeoplasmsEgfr
CarcinomaEgfr
Carcinoma, EndometrioidEgfr
Carcinoma, HepatocellularEgfr
Carcinoma, Non-Small-Cell LungEgfr
Carcinoma, Renal CellEgfr
Carcinoma, Squamous CellEgfr
Carcinoma, Squamous Cell of Head and NeckEgfr
Carcinoma, Transitional CellEgfr
CardiomegalyEgfr
Cardiomyopathy, DilatedEgfr
ChloracneEgfr
CholangiocarcinomaEgfr
Colonic NeoplasmsEgfr
Colorectal NeoplasmsEgfr
Craniofacial AbnormalitiesEgfr
DementiaEgfr
Diabetes Mellitus, ExperimentalEgfr
Diabetes Mellitus, Type 1Egfr
Diabetes Mellitus, Type 2Egfr
Diabetic RetinopathyEgfr
Disease ProgressionEgfr
EndometriosisEgfr
Esophageal NeoplasmsEgfr
Esophageal Squamous Cell CarcinomaEgfr
Esophagitis, PepticEgfr
Gallbladder NeoplasmsEgfr
GlioblastomaEgfr
GliomaEgfr
Hamartoma Syndrome, MultipleEgfr
Head and Neck NeoplasmsEgfr
Huntington DiseaseEgfr
HyperplasiaEgfr
Hypersensitivity, ImmediateEgfr
HypertensionEgfr
Hypertension, PulmonaryEgfr
Hypertrophy, Left VentricularEgfr
InflammationEgfr
INFLAMMATORY SKIN AND BOWEL DISEASE, NEONATAL, 2Egfr
Insulin ResistanceEgfr
Laryngeal NeoplasmsEgfr
lung cancerEgfr
Lung DiseasesEgfr
Lung NeoplasmsEgfr
Lymphatic MetastasisEgfr
Mammary Neoplasms, AnimalEgfr
Mammary Neoplasms, ExperimentalEgfr
MesotheliomaEgfr
Mesothelioma, MalignantEgfr
Nasopharyngeal NeoplasmsEgfr
Neoplasm InvasivenessEgfr
Neoplasm MetastasisEgfr
Neoplasm Recurrence, LocalEgfr
ObesityEgfr
OsteosarcomaEgfr
Ovarian NeoplasmsEgfr
Pancreatic NeoplasmsEgfr
PapillomaEgfr
Parkinson DiseaseEgfr
Parkinsonian DisordersEgfr
Phyllodes TumorEgfr
Pleomorphic Xanthoastrocytoma Egfr
Polycystic Kidney, Autosomal RecessiveEgfr
Prostatic NeoplasmsEgfr
Pulmonary Disease, Chronic ObstructiveEgfr
Pulmonary FibrosisEgfr
Rectal NeoplasmsEgfr
SchizophreniaEgfr
Small Cell Lung CarcinomaEgfr
Spinal Cord InjuriesEgfr
Squamous Cell Carcinoma of the LungEgfr
Squamous Cell Carcinoma of the TongueEgfr
Stomach NeoplasmsEgfr
Tobacco Use DisorderEgfr
Urinary Bladder NeoplasmsEgfr
Uterine Cervical NeoplasmsEgfr
Pathway Annotations Associated with Genes in the gefitinib pharmacodynamics pathway
Phenotype Annotations Associated with Genes in the gefitinib pharmacodynamics pathway

References Associated with the gefitinib pharmacodynamics pathway:

Ontology Path Diagram:

paths to the root

Import into Pathway Studio: